4D Molecular Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
4D Molecular Therapeutics, Inc. (FDMT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 3.18 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 516.60K shares, a 228.00% increase year-over-year.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 2.66M shares, a 87.10% increase year-over-year.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 525.50K shares, a 18.16% decline year-over-year.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 291.00K shares, a 60.95% decline year-over-year.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 2.40M shares, a 31.50% increase from fiscal 2024.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.82M shares, a 52.37% decline from fiscal 2023.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 3.82M shares, a 41.12% increase from fiscal 2022.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.71M shares, a 73.06% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 516.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 3.18M shares 10-Q · filed 2026-08-13 | 3.70M shares derived: sum of 3 quarters · filed 2026-08-13 | 3.99M shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 2.66M shares 10-Q · filed 2026-05-07 | 3.19M shares derived: sum of 2 quarters · filed 2026-05-07 | 3.48M shares derived: sum of 3 quarters · filed 2026-05-07 | 3.63M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 525.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | 816.50K shares derived: sum of 2 quarters · filed 2026-03-18 | 974.00K shares derived: sum of 3 quarters · filed 2026-03-18 | 2.40M shares 10-K · filed 2026-03-18 |
| 2025-09-30 | 291.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 448.50K shares derived: sum of 2 quarters · filed 2025-11-10 | 1.87M shares 10-Q · filed 2025-11-10 | 2.51M shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 157.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 1.58M shares 10-Q · filed 2025-08-11 | 2.22M shares derived: sum of 3 quarters · filed 2025-08-11 | 2.97M shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | 1.42M shares 10-Q · filed 2025-05-08 | 2.06M shares derived: sum of 2 quarters · filed 2025-05-08 | 2.81M shares derived: sum of 3 quarters · filed 2025-05-08 | 2.96M shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 642.14K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | 1.39M shares derived: sum of 2 quarters · filed 2025-02-28 | 1.54M shares derived: sum of 3 quarters · filed 2025-02-28 | 1.82M shares 10-K · filed 2025-02-28 |
| 2024-09-30 | 745.25K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 893.75K shares derived: sum of 2 quarters · filed 2024-11-13 | 1.18M shares 10-Q · filed 2024-11-13 | 3.78M shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 148.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 434.50K shares 10-Q · filed 2024-08-08 | 3.03M shares derived: sum of 3 quarters · filed 2024-08-08 | 3.13M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 286.00K shares 10-Q · filed 2024-05-09 | 2.88M shares derived: sum of 2 quarters · filed 2024-05-09 | 2.98M shares derived: sum of 3 quarters · filed 2024-05-09 | 3.05M shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 2.60M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 2.70M shares derived: sum of 2 quarters · filed 2024-02-29 | 2.77M shares derived: sum of 3 quarters · filed 2024-02-29 | 3.82M shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 97.90K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 169.50K shares derived: sum of 2 quarters · filed 2023-11-09 | 1.23M shares 10-Q · filed 2023-11-09 | 1.30M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 71.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 1.13M shares 10-Q · filed 2023-08-09 | 1.20M shares derived: sum of 3 quarters · filed 2023-08-09 | 2.34M shares derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | 1.06M shares 10-Q · filed 2023-05-11 | 1.13M shares derived: sum of 2 quarters · filed 2023-05-11 | 2.27M shares derived: sum of 3 quarters · filed 2023-05-11 | 2.60M shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 68.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | 1.21M shares derived: sum of 2 quarters · filed 2023-03-15 | 1.54M shares derived: sum of 3 quarters · filed 2023-03-15 | 2.71M shares 10-K · filed 2023-03-15 |
| 2022-09-30 | 1.14M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 1.47M shares derived: sum of 2 quarters · filed 2022-11-08 | 2.64M shares 10-Q · filed 2022-11-08 | 2.78M shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 330.05K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 1.50M shares 10-Q · filed 2022-08-11 | 1.64M shares derived: sum of 3 quarters · filed 2022-08-11 | 1.82M shares derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | 1.17M shares 10-Q · filed 2022-05-12 | 1.31M shares derived: sum of 2 quarters · filed 2022-05-12 | 1.49M shares derived: sum of 3 quarters · filed 2022-05-12 | 1.95M shares derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-12-31 | 141.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | 325.40K shares derived: sum of 2 quarters · filed 2022-03-28 | 779.05K shares derived: sum of 3 quarters · filed 2022-03-28 | 1.57M shares 10-K · filed 2022-03-28 |
| 2021-09-30 | 183.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 637.25K shares derived: sum of 2 quarters · filed 2021-11-10 | 1.42M shares 10-Q · filed 2021-11-10 | |
| 2021-06-30 | 453.65K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 1.24M shares 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | 787.10K shares 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | 1.32M shares 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |